
ASRT Stock Forecast & Price Target
ASRT Analyst Ratings
Bulls say
Assertio Hldgs is well-positioned for growth in the pharmaceutical industry due to its diverse and differentiated product portfolio, with a particular focus on the high-demand oncology market. The company's strong commercial capabilities allow it to effectively market and sell its products, leading to steady revenue growth and strong financial performance. As a result, the positive outlook for Assertio Hldgs is supported by its reliable revenue streams and potential for continued expansion in the future.
Bears say
Assertio Hldgs is in a significant shift phase, as it recently agreed to be acquired by Garda Therapeutics for $18 per share. This is a 34.6% premium to the company's unaffected stock price on March 20, 2026, and a 46.6% premium to the 30-day unaffected volume-weighted average price (VWAP). The deal was unanimously approved by both companies' boards, with the potential for a CVR tied to future milestones for a legacy product with low revenue potential. Due to this significant shift and limited upside potential, the analyst downgraded their rating on the stock to Neutral with a revised price target of $18 per share.
This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ASRT Analyst Forecast & Price Prediction
Start investing in ASRT
Order type
Buy in
Order amount
Est. shares
0 shares